Handelsbanken Fonder’s Keros Therapeutics KROS Stock Holding History

Handelsbanken Fonder’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,800	Closed	-$110K	–	1541
2025 Q1	$110K	Hold	10,800	–	–	﹤0.01%	1517
2024 Q4	$171K	Buy	10,800 +1,100	+11%	+$57.2K	﹤0.01%	1522
2024 Q3	$563K	Buy	9,700 +1,700	+21%	+$84K	﹤0.01%	1198
2024 Q2	$366K	Buy	8,000 +1,300	+19%	+$69.9K	﹤0.01%	1298
2024 Q1	$444K	Hold	6,700	–	–	﹤0.01%	1214
2023 Q4	$266K	Hold	6,700	–	–	﹤0.01%	1428
2023 Q3	$214K	Hold	6,700	–	–	﹤0.01%	1448
2023 Q2	$269K	Sell	6,700 -600	-8%	-$26.3K	﹤0.01%	1384
2023 Q1	$312K	Hold	7,300	–	–	﹤0.01%	1271
2022 Q4	$351K	Buy	+7,300	New	+$341K	﹤0.01%	1160
2022 Q2	–	Sell	-7,400	Closed	-$402K	–	1658
2022 Q1	$402K	Hold	7,400	–	–	﹤0.01%	1350
2021 Q4	$433K	Buy	+7,400	New	+$369K	﹤0.01%	1449

Other funds holding KROS

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Handelsbanken Fonder's KROS Position: Q2 2025 in Review

Handelsbanken Fonder sold out of Keros Therapeutics (KROS) in Q2 2025, closing a stake of 10,800 shares — an estimated $110K sold.

Handelsbanken Fonder first reported a position in KROS in Q4 2021 and held it in 12 quarters. The position peaked at $563K in Q3 2024. 139 funds tracked by Wall St. Rank hold KROS as of Q2 2025.

Handelsbanken Fonder reported no remaining Keros Therapeutics position as of Q2 2025 after selling out during the quarter.
Handelsbanken Fonder sold 10,800 Keros Therapeutics shares in Q2 2025, an estimated $110K.
Handelsbanken Fonder first reported a position in Keros Therapeutics in Q4 2021 and held it in 12 quarters.
Handelsbanken Fonder's Keros Therapeutics position peaked at $563K in Q3 2024.
139 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2025.

Based on Handelsbanken Fonder's 13F filing for Q2 2025, filed 12 Aug 2025.